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1.1 Parkinson’s disease and Lewy bodies 
Parkinson’s disease (PD) is the most prevalent neurodegenerative disease that affects motor 
control, although dementia, depression, and other psychiatric symptoms are occasionally 
present (reviewed in Jankovic, 2008). The motor symptoms include resting tremors, 
bradykinesia/akinesia, rigidity, and postural instability, and are associated with the death 
of dopaminergic neurons in the substantia nigra pars compacta (SNpc) (Lloyd and 
Hornykiewicz, 1970; reviewed in Saper, 1999) and noradrenergic neurons in the locus 
coeruleus (Mann and Yates, 1983; Gaspar et al., 1991). Degeneration of these neurons 
disrupts basal ganglia circuitry of the brain and interferes with the initiation of voluntary 
movement (Levy et al., 1997).  
Another pathological characteristic of the disease is the presence of the intracellular protein 
aggregates known as Lewy bodies and Lewy neurites (Hughes et al., 1992), described initially 
by Frederick Lewy in 1912, that were associated with dying dopaminergic neurons in the 
SNpc by Tretiakoff (reviewed in Holdorff, 2006). Lewy bodies are also present in other brain 
regions outside the SNpc, and may appeat first in the glossopharyngeal, vagal, and olfactory 
centres (Braak et al., 2003). The disruption of these regions is now linked to a preclinical phase 
of PD that includes perturbations of smell, gastrointestinal motility, and sleep patterns prior to 
the development of motor impairments coincident with neurodegeneration and inclusions in 
the midbrain. These intraneuronal aggregates are composed of lipids and various proteins 
including ┙-synuclein, ubiquitin, and neurofilaments (Spillantini et al., 1998; reviewed in 
Cookson, 2005). Whether Lewy bodies directly cause cytotoxicity or are formed as 
compensatory activation of survival pathways remains under debate. Nevertheless, the 
presence of Lewy bodies is an essential component of post-mortem diagnoses of PD (Christine 
and Aminoff, 2004; reviewed in Jankovic, 2008). 
1.2 α-Synuclein in Parkinson’s disease 
┙-Synuclein is important to understanding the etiology of PD both because it is the main 
pathological component of Lewy bodies and because mutations and changes in its 
expression are linked to familial PD. Three missense mutations causing single amino acid 
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substitutions in ┙-synuclein are linked to autosomal dominant forms of familial PD: A53T, 
A30P, and E46K (Polymeropoulos et al., 1997; Kruger et al., 1998; Zarranz et al., 2004). 
Interestingly, in many mammalian species, including mice and new world primates, 
threonine is the normal residue at position 53, which suggest some kind of corrective 
mechanism elsewhere in the coding sequence to reduce the toxicity of the A53T mutation 
(Hamilton, 2004). Elevated expression of normal ┙-synuclein is also pathogenic as gene 
triplication or duplication is linked to early- or late-onset PD, respectively (Singleton et al., 
2003; Chartier-Harlin et al., 2004). 
Despite the efforts of many research laboratories since its initial discovery as an abundant 
presynaptic protein in cholinergic nerve terminals innervating the Torpedo electric organic 
(Maroteax et al, 1988), ┙-synuclein’s function still remains somewhat of a mystery. Mice 
deficient in ┙-synuclein are unremarkable, but exhibit increased release of dopamine under 
paired-pulse stimuli and reduced striatal tissue content of dopamine (Abeliovich et al., 
2000). Over-expression of ┙-synuclein in yeast leads to aggregation of vesicles, disruption in 
vesicular transport, and death (Gitler et al., 2008; Soper et al., 2008). Similarly, moderate ┙-
synuclein over-expression in mammalian neurons reduces transmitter release and the 
number of synaptic vesicles arrayed at presynaptic active zones (Nemani et al., 2010). These 
reports clearly implicate ┙-synuclein in synaptic vesicle mobilization or fusion, but offer 
little information about its pathogenic role.  
In vitro studies revealed that A30P and A53T mutant ┙-synuclein form oligomers at a faster 
rate than wild-type ┙-synuclein (Conway et al., 2000). Post-translational modifications may 
also affect ┙-synuclein aggregation, as phosphorylation of serine at position 129 is highly 
upregulated in Lewy bodies (Fujiwara et al., 2002). Phosphomimic residue changes, such as 
serine 129 to aspartate, which simulates the charge distribution of phosphorylation, cause 
neuronal loss in fruit flies and substitution of serine 129 with alanine, which prevents 
phosphorylation, rescues this cell loss (Chen and Feany, 2005). However, experimental 
evidence for the toxicity of serine 129 phosphorylation is somewhat equivocal in rodents, 
because expression of ┙-synuclein with alanine 129 is as toxic as aspartate 129 (Gorbatyuk et 
al, 2008; McFarland et al., 2009).  
Although ┙-synuclein is decreased in the cerebrospinal fluid of PD patients (Mollenhauer et 
al, 2011), there is an increase in ┙-synuclein oligomers suggesting that ┙-synuclein 
aggregation and its leakage from neurons is accelerated in PD (Tokuda et al., 2010). 
However, the mechanistic contribution of ┙-synuclein to neuronal death in PD still remains 
unclear. Low nanomolar concentrations of ┙-synuclein are neuroprotective against the 
oxidative insults of hydrogen peroxide and 6-hydroxydopamine, whereas higher 
micromolar concentrations are toxic (Batelli et al., 2008). This suggests that ┙-synuclein may 
be neuroprotective and toxic at low and high levels, respectively, and is in accord with the 
pathogenic effects of SNCA duplication or triplication. ┙-Synuclein has also been shown to 
cause oxidative stress through direct damage to mitochondria. For example, mitochondrial 
import of ┙-synuclein mediated by a cryptic targeting signal can disrupt complex 1 activity 
(Devi et al., 2008), and ┙-synuclein over-expression in nematodes and mammalian cells 
induced fragmentation of mitochondria (Kamp et al., 2010; Nakamura et al., 2011). Co-
expression of PINK1, parkin, and DJ-1 protect against mitochondrial fragmentation, 
consistent with the notion that these three proteins function in a common mitochondrial 
pathway leading to PD pathology. The convergence of ┙-synuclein to a mitochondrial role 
when expressed at sufficient levels could therefore be viewed as a pathogenic pathway that 
diverges from its normal physiological role in vesicle trafficking.  
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1.3 -Synuclein outside of disease 
A role in synaptic function is implicated from the observation that ┙-synuclein is highly 
concentrated in pre-synaptic terminals (Jakes et al., 1994; George et al., 1995) and that ┙-
synuclein disperses reversibly from these presynaptic terminals in response to brief neural 
activity (Fortin et al., 2005). The dispersion is attenuated by tetanus toxin, which inactivates 
vesicle fusion but not the preceding ion fluxes, suggesting that ┙-synuclein solubility is 
directly linked to exocytosis. While these results do not suggest a presynaptic function for ┙-
synuclein, other studies with ┙-synuclein knockout mice reveal increased nigrostriatal 
dopamine release induced by paired-pulse stimuli (Abeliovich et al., 2000), implicating ┙-
synuclein as a negative regulator of a readily-releasable vesicle pool of dopamine. In 
contrast, another line of ┙-synuclein null mice showed normal response to single or paired 
stimuli, but deficits in response to trains of stimuli which rely on reserve vesicle recruitment 
and a reduction in the number distal vesicles (Cabin et al., 2002). To explore whether ┚-
synuclein compensates for loss of ┙-synuclein, removal of both ┙- and ┚-synuclein 
decreased total brain dopamine by 20% as well as complexins and 14-3-3 proteins (Chandra 
et al., 2004). Complexins are a regulatory component of the SNARE (soluble N-
ethylmaleimide-sensitive attachment protein receptor) complexes involved in synaptic 
vesicle fusion (Hu et al., 2002). However, the other previously described aberrations such as 
synaptic vesicle reduction, electrophysiological changes, and dopamine re-uptake were not 
observed in these ┙-synuclein knockout mice. Despite the differences, ┙-synuclein knockout 
mice display subtle alterations in vesicle storage and dynamics. 
The converse experimental paradigm using over-expression of ┙-synuclein also suggests 
that it inhibits synaptic transmission in primary neurons and intact ex vivo brain (Nemani et 
al., 2010). Morphological and electrophysiological analyses indicate that the reduction was 
due to decreased readily-releasable synaptic vesicles, but not the overall number of synaptic 
vesicles, consistent with the notion that ┙-synuclein is a negative regulator of the synaptic 
vesicle mobilization. 
Recent studies using biochemical approaches have reported that ┙-synuclein disrupts 
arachidonic acid-mediated stabilization of soluble N-ethylmaleimide sensitive fusion 
protein receptor (SNARE) complex (comprised of syntaxin-1, SNAP25, and synaptobrevin-
2) that is essential for synaptic vesicle fusion (Darios et al., 2010). Although this study did 
not co-immunoprecipitate ┙-synuclein with members of the SNARE complex, thus 
suggesting an indirect interaction, others have reported ┙-synuclein binding with 
synaptobrevin-2 and proposed that this binding stabilizes the SNARE complex (Burre et al., 
2010). Interestingly, loss of assembled SNARE complexes in mice deficient for cysteine-
string protein alpha (CSP┙) can be rescued by ┙-synuclein over-expression and worsened by 
its knockdown. The loss of all three synucleins (┙-, ┚-, and ┛-) causes premature death due 
to neurological symptoms, suggesting that ┚- and/or ┛-synuclein perform redundant 
functions and compensate for ┙-synuclein deficiency in the single knockout animals. Thus, 
┙-synuclein exerts a regulatory effect on SNARE complex formation, but its mechanism 
remains poorly defined. 
Some studies have suggested that ┙-synuclein may regulate vesicle trafficking more broadly 
that just in synaptic transmission. Expression of ┙-synuclein in yeast and mammalian cells 
causes delays in ER-to-Golgi vesicle trafficking, an effect that was more striking with the 
A53T mutant (Cooper et al., 2006; Thayanidhi et al., 2010). These changes in ER-to-Golgi 
trafficking by ┙-synuclein may be caused by immobilizing vesicles in the cytoplasm (Soper 
et al., 2008). The mechanism appears to involve rab proteins, small GTPases that regulate 
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vesicle trafficking, as the impairment is rescued by overexpressing certain rab proteins 
(Gitler et al., 2008). Furthermore, as yeast do not express ┙-synuclein endogenously, these 
studies suggest that ┙-synuclein can interact with both constitutive and Ca2+-dependent 
vesicle trafficking machineries that is conserved between yeast and higher organisms. 
2. -Synuclein and membrane-binding 
2.1 The structure of -synuclein and how it contributes to membrane-binding 
The structure of ┙-synuclein can be divided into three domains: an amino-terminal domain 
with seven imperfect KTKEGV repeats, a central domain essential for aggregation called the 
non-amyloid┚ component (NAC), and a hydrophilic carboxyl-terminal tail (Clayton and 
George, 1998) (Fig. 1.1A). The amino-terminal repeats, which are similar to sequences found 
in apolipoproteins, form amphipathic helices with polar and non-polar residues aligned in 
opposing direction and allow ┙-synuclein to immerse partially into lipid membranes (Fig. 
1.1B). The capacity of ┙-synuclein to bind freely to membranes has been demonstrated (Jo et 
al., 2000; Conway et al., 2000). The helical structure of ┙-synuclein upon binding to sodium 
dodecyl sulfate (SDS)-soluble micelles has been established using nuclear magnetic 
 
 
Fig. 1. The primary structure of human ┙-synuclein. (A) The structure itself can be divided 
into three unequal regions: the imperfect KTKEGV repeats believed to form a helical 
structure on phospholipid membranes, the non-A┚ component (NAC) seen in Alzheimer 
disease-associated plaques, and a non-membrane-associated acidic c-terminal tail. (B) Upon 
binding to membranes, ┙-synuclein assumes a helical conformation due to the amphipathic 
nature of the KTKEGV repeats. All three amino acid substitution sites associated with 
familial forms of PD (A30P, E46K, and A53T) can be found in the amphipathic repeat region. 
The serine 129 site commonly found to be phosphorylated in Lewy bodies can be found in 
the acidic tail. Note that the residue in position 53 is naturally a threonine instead of an 
alanine in many mammalian species, including rodents. 
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resonance and electron spin resonance studies (Jao et al., 2004; Ulmer et al., 2005; Borbat et 
al., 2006). The helical conformation is energetically favourable when compared to the 
unstructured conformation of cytosolic ┙-synuclein. 
2.2 Implications of -synuclein membrane-binding 
Binding to and dissociation from the synaptic membrane may be linked to regulating the 
still-undefined function of ┙-synuclein. Using fluorescent imaging to visualize GFP-tagged 
┙-synuclein, depolarization reversibly induced the redistribution of ┙-synuclein from 
synaptic boutons to the perisynaptic region (Fortin et al., 2005), consistent with the 
dissociation of ┙-synuclein from synaptic vesicles prior to exocytosis. This link between ┙-
synuclein, its membrane binding, and exocytosis is consistent with other reports that ┙-
synuclein regulates SNARE complex assembly (Darios et al., 2010; Burre et al, 2010). 
The membrane-binding properties of ┙-synuclein may also have implications in PD 
pathogenesis. The addition of lipid vesicles causes a greater proportion of ┙-synuclein to 
assume an ┙-helical conformation and decreases the fibrillization of ┙-synuclein (Zhu et al., 
2003); Jo et al., 2004), suggesting that increased membrane binding may be protective 
against Lewy body pathology. However, other studies adding phospholipids to ┙-synuclein 
induced fibril formation (Narayanan and Scarlata, 2001; Cole et al., 2002). Mutant A30P ┙-
synuclein exhibits a lower propensity to bind to phospholipid membranes as determined in 
vitro (Jo et al., 2002), but forms oligomers faster than wild-type or A53T ┙-synuclein 
(Conway et al., 2000). Nevertheless, the A53T mutant ┙-synuclein forms fibrils (the likely 
precursor to Lewy bodies) at a higher rate. Furthermore, a rotenone model of PD revealed 
that lipids co-stained with ┙-synuclein aggregates (Lee et al., 2002), suggesting that lipids 
may enable Lewy body formation. Taken together, the evidence is conflicting on whether 
the membrane-bound or cytosolic ┙-synuclein is the precursor for aggregated ┙-synuclein 
and Lewy body pathology, although it remains possible that oligomerization and 
fibrillization could occur in distinct cellular compartments (Auluck et al., 2010). 
2.3 Regulation of -synuclein membrane-binding 
While there remains some uncertainty as to whether the membrane-bound or cytosolic ┙-
synuclein is more pathologically relevant, it is also important to understand the mechanisms 
regulating the exchange between these two pools. We have previously suggested that brain 
cytosolic factors are critical in facilitating ┙-synuclein dissociation and association from 
synaptic membranes (Wislet-Gendebien et al., 2006; 2008). The remainder of this chapter 
will be devoted to describing some of these cytosolic factors that were characterized using 
our cell-free assays. 
3. Key techniques for examining the regulation of membrane-binding 
3.1 Fractionation into membrane-bound and cytosolic proteins 
Much of our current understanding of ┙-synuclein conformation and membrane interactions 
are based on studies with recombinant ┙-synuclein purified from bacteria and bound to 
artificial membranes. This approach has yielded a wealth of information on the biophysical 
characteristics of normal and mutant ┙-synuclein and their affinity for specific lipids. 
However, recombinant ┙-synuclein and artificial membranes provide no basis for the 
understanding ┙-synuclein behaviour in vivo, in particular its ability to exchange between 
membrane and cytosol within neurons, where the compartmentalization of ┙-synuclein is 
modulated by intracellular components and neuronal activity.  
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To understand endogenous intracellular regulation of ┙-synuclein dynamics, reconstitution 
of its membrane binding and dissociation can be studied using semi-intact or cell-free 
assays. For example, the use of hypotonic lysis to disrupt neuronal plasma membrane 
releases freely-diffusible cytoplasmic components and permits measurement of subtle shifts 
in ┙-synuclein membrane-binding (Fig. 2). Experiments of this type are best done with 
endogenously expressed ┙-synuclein, although where exogenous expression is required, 
consideration should be given to the extent of ┙-synuclein overexpression so as not to 
saturate the membrane compartment and cause artifactually low membrane-bound to 
cytosolic ratio of ┙-synuclein, as excess ┙-synuclein will accumulate in cytosol. 
Measurement of ┙-synuclein dynamics in intact cells may be limited by an inability to assess 
whether changes in membrane-bound and cytosolic ┙-synuclein are caused by perturbations 
in ┙-synuclein dissociation or binding kinetics. This can be overcome by using cell-free 
assays (such as those described below) that monitor the unidirectional movement of ┙-
synuclein from a ”donor” fraction expressing ┙-synuclein to an “acceptor” fraction derived 
from an ┙-synuclein-deficient mouse or cells. 
 
 
Fig. 2. A schematic overview of fractionation. Synaptosomes or cells were hypotonically 
lysed in either distilled water or a hypotonic buffer. The lysates were centrifuged and the 
supernatant (S) and pellet (P) fractions were processed separately. S fractions were 
centrifuged again to remove residual synaptic vesicles and supernatants were kept as 
cytosolic fractions. The P fractions were resuspended in buffer containing 1% CHAPS or 1% 
Triton X-100. Lysates were centrifuged and the supernatants were kept as membrane 
fraction. 
3.2 -Synuclein dissociation and binding assays 
While analyzing the ratio of membrane-bound to cytosolic ┙-synuclein can yield useful data 
in an in-vivo or ex-vivo setting, it does not provide information on whether effects are taking 
place in the membrane-dissociation or membrane-binding step of ┙-synuclein dynamics. 
This question can be answered by employing cell-free assays we have previously published 
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(Wislet-Gendebien et al., 2006). To measure ┙-synuclein dissociation, synaptosomal 
membranes from either non-transgenic or ┙-synuclein transgenic mice are incubated with 
brain cytosol isolated from ┙-synuclein deficient mice. By measuring the amount of ┙-
synuclein dissociated from the membrane and into the cytosol under different conditions, it 
is possible to determine whether specific cellular factors affect ┙-synuclein membrane-
dissociation.  
A converse protocol was developed to assess ┙-synuclein binding to synaptic membrane 
(Wislet-Gendebien et al., 2008). In this assay, ┙-synuclein can be prepared from 2 different 
origins: either 1) purified E.coli-expressed ┙-synuclein mixed with cytosol from ┙-synuclein 
deficient mouse brains, or 2) cytosol prepared from transgenic mice overexpressing the 
human form of wild-type or mutant ┙-synuclein. Either of the two sources of ┙-synuclein is 
then combined with synaptic membrane prepared from ┙-synuclein deficient mouse 
synaptosomes. Membrane-bound ┙-synuclein can then be analyzed as a measure of ┙-
synuclein membrane-binding in response to various controlled factors such as 
pharmacological agents or lipids. This assay can provide information on whether a certain 
condition or factor is affecting ┙-synuclein membrane-binding.  
The key benefit of these dissociation and binding assays is the ability to probe the 
intracellular milieu with specific reagents, such as antibodies, recombinant mutants, or 
peptide domains, which are membrane impermeant. However, because these assays 
depends on mixing separately-derived membrane and cytosolic fractions, one of which 
must be ┙-synuclein-deficient, there is an inherent limitation to assess the dissociation or 
binding of other synaptic proteins due to their presence in both the membrane and the 
cytosol of both assays. However, these assays can be adapted to analyze the dissociation and 
binding of other synaptic proteins provided that transgenic animals deficient in the protein 
of interest are available. 
4. Factors involved in regulating -synuclein membrane-binding 
4.1 Brain cytosol 
The ┙-synuclein dissociation assay revealed that stably membrane-bound ┙-synuclein can 
be recruited into the cytosol in the presence of brain cytosolic proteins (Wislet-Gendebien et 
al., 2006). Pre-digestion with trypsin or preheating at 95 °C of the cytosol eliminated its 
ability to induce ┙-synuclein dissociation, directly implicating a role for specific cytosolic 
proteins in controlling ┙-synuclein solubility. Moreover, the permissive factors required to 
mediate ┙-synuclein dissociation from the membrane appeared to be enriched in brain 
cytosol, as a 6-fold greater concentration of liver cytosol was required to achieve equivalent 
┙-synuclein dissociation using brain cytosol. The proteins triggering ┙-synuclein 
dissociation were in limited quantity in cytosol and were not regenerated under our assay 
conditions. A single exposure to synaptosomal membranes was sufficient to deplete the 
capacity of the cytosol to extract membrane ┙-synuclein so that subsequent incubations with 
fresh membranes yielded no additional dissociated ┙-synuclein. In contrast, presynaptic 
membranes retained ample extractable ┙-synuclein, which could be dissociated with 
subsequent applications of fresh cytosol. We also showed that the cytosolic activity that 
mediated ┙-synuclein dissociation clearly distinguished between wild-type ┙-synuclein and 
PD-associated mutants. The cytosol-dependent off-rate for both A30P and A53T ┙-synuclein 
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4.2 Cytosolic lipids 
Using our ┙-synuclein binding assay, we observed that cytosol-mediated ┙-synuclein 
membrane-binding was heat stable and protease insensitive. Further characterization 
revealed that ATP and lipids are two of the main cytosolic components that modulate ┙-
synuclein binding to synaptic membranes (Wislet-Gendebien et al., 2008). We proposed that 
endogenous cytosolic lipids transferred to membranes prior to ┙-synuclein recruitment or 
bound directly to cytosolic ┙-synuclein may aid ┙-synuclein folding at the lipid-cytoplasm 
interface so that it is more amenable to binding directly to synaptic membranes. To provide 
further insight into this novel protein-lipid-protein interaction, we profiled 
glycerophosphocholines bound to proteins in ┙-synuclein-deficient cytosol by nanoflow LC-
ESI-MS and precursor ion scan. Our analysis identified 24 species that can potentially affect 
┙-synuclein membrane interactions, including platelet activating factor, which was able to 
reconstitute the activity of delipidated cytosol.  
4.3 Rab3a 
Interestingly, our binding experiments also revealed that the association of ┙-synuclein to 
synaptic membranes could be stabilized by brief formaldehyde-induced cross-linking, 
which generates very short intermolecular covalent bonds. This suggested that ┙-synuclein 
binding is partly dependent on one or more synaptic vesicle proteins for recruitment. There 
are several candidate vesicular proteins that have been proposed to interact with ┙-
synuclein, including cysteine string protein, rab3a, and synaptobrevin-2 (Chandra et al., 
2005; Gitler et al., 2008; Burre et al., 2010). As a potential test to identify the ┙-synuclein 
receptive component on synaptic vesicles, when we screened the ability of antibodies 
against synaptic vesicle proteins to inhibit ┙-synuclein membrane binding, rab3a antibodies 
effectively reduced ┙-synuclein membrane binding. Moreover, exposure of membranes to 
rab3a antibody prior to incubation with ┙-synuclein was sufficient, whereas treatment of ┙-
synuclein-containing cytosol with the antibody has no effect, suggesting that ┙-synuclein 
binding is facilitated by vesicle bound rab3a (Chen and Tandon, unpublished). 
Similarities in localization and membrane-binding have previously suggested an interaction 
between rab3a and ┙-synuclein, at least under pathological conditions. Immunoprecipitation 
studies revealed ┙-synuclein interaction with rabphilin in brains from individuals with diffuse 
Lewy body disease and multiple system atrophy (Dalfo et al., 2004a; 2005). In addition, A30P 
┙-synuclein in transgenic mouse brain was found to co-elute with rab3a, rab5, and rab8, 
suggesting that ┙-synuclein may interact with a broad range of rab proteins (Dalfo et al., 
2004b). From a functional perspective, ┙-synuclein appears to antagonize rab3a function. For 
example, over-expression of ┙-synuclein in yeast interfered with ER-to-Golgi vesicle 
trafficking that was corrected by the simultaneous over-expression of the yeast homologue of 
rab1 (Cooper et al., 2006; Soper et al., 2008). Similarly, elevated toxicity in nematodes and rat 
primary neurons engineered to express wild-type or A53T ┙-synuclein was rescued by the 
addition of rab8 or rab3a (Gitler et al., 2008). In all these studies, ┙-synuclein toxicity was 
corrected by over-expressing rab proteins, suggesting that the over-expression of ┙-synuclein 
disrupted rab-mediated vesicle targeting and docking. 
Rab3a is a small GTPase that regulates synaptic vesicle targeting, docking, and fusion, and 
like other members of the rab family, it’s cycling between vesicles and cytosol is regulated 
by the phosphorylation state of its guanine nucleotide (GTP/GDP). Dissociation of rab3a 
from synaptic vesicles is coupled to the calcium-influx that initiates exocytosis (Fischer von 
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Mollard et al., 1991). The molecular machinery that mediates rab3a cycling has been 
extensively characterized. After GTP cleavage, rab3a is retrieved off vesicles by guanine-
nucleotide dissociation inhibitor (GDI) complex that includes Hsp90, such that the Hsp90 
inhibitors radicicol and geldanamycin prevent rab3a dissociation from synaptic membranes 
(Sakisaka et al., 2002). Using our ┙-synuclein dissociation assay, we found that the Hsp90 
inhibitors also caused an accumulation of ┙-synuclein on synaptic membranes, providing 
support for argument that ┙-synuclein membrane association is closely linked to that of 
rab3a and is regulated by the GDI/Hsp90 chaperone complex (Chen and Tandon, 
unpublished). In accordance with this, expression of a constitutively GTP-bound, dominant-
negative rab3a mutant also induced an increase in membrane-bound ┙-synuclein suggesting 
that GTP/GDP conversion by rab3a is a precondition for the liberation of vesicular ┙-
synuclein. Together, our results suggest that rab3a and its recycling machinery regulate ┙-
synuclein membrane-binding and dissociation (Fig. 3). 
 
 
Fig. 3. A model whereby rab3a regulates dissociation of ┙-synuclein from synaptic 
membranes. GTP-bound rab3a binds to ┙-synuclein on the membrane. After GTP-hydrolysis 
mediated by a GTPase activating protein (GAP), rab3a is chaperoned off of the membrane 
by the GDP-dissociation inhibitor complex (GDI complex) and ┙-synuclein also dissociates 
from the membrane. Whether ┙-synuclein dissociation is transiently mediated by the GDI 
complex or is because of the loss of membrane-bound rab3a is yet to be determined. 
Whether these results have any implications on the etiology of synucleinopathies is unclear 
and there are no rab3a mutations linked to PD. However, the interaction with rab3a 
reinforces ┙-synuclein’s close relationship with the machinery controlling synaptic vesicle 
trafficking. Further research is needed on how ┙-synuclein fits into the broader picture of 
the exocytic pathway and how subtle changes to ┙-synuclein disposition may disturb vesicle 
dynamics and lead to pathology.  
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There is now ample evidence that ┙-synuclein is involved in the regulation of synaptic 
vesicle trafficking and, more recently, in mitochondrial fission/fusion machinery. Whether 
its role in maintaining these different organelles occurs concurrently in healthy neurons is 
not known, though it may be instructive to consider the levels of expression required for 
apparent modulation of vesicle mobilization or mitochondrial dynamics. The effects of ┙-
synuclein on mitochondrial morphology have been noted in only two studies thus far, both 
requiring transient overexpression and not in models of normal or stable ┙-synuclein 
expression (Kamp et al., 2010; Nakamura et al., 2011). If this observation holds in future 
analyses, it may represent a segregation of ┙-synuclein activity based on its expression level, 
whereby lower levels of ┙-synuclein impart direct effects on synaptic vesicle behaviour and 
high ┙-synuclein concentration disrupts normal mitochondrial division and turnover. This 
dual activity may also explain the biphasic nature of ┙-synuclein toxicity, being beneficial at 
lower expression levels and increasing in toxicity at higher concentration, particularly in 
combination with oxidative stress. Moreover, a gain-of-function pathogenic link between ┙-
synuclein and mitochondria fits well into a biological cascade that is opposed by expression 
of PINK1, parkin, or DJ-1, which are now recognized as controlling mitochondrial 
fission/fusion and mitophagy.  
It is clear that direct interaction of ┙-synuclein with lipid membranes is necessary to 
propagate its biological function. Regardless of the organelle interaction, it is reasonable to 
assume that the binding ┙-synuclein to various organelle membranes is likely to involve a 
common mechanism whereby the amino-terminal half of ┙-synuclein folds into an 
amphipathic ┙-helix for partial immersion into the lipid bilayer. However, additional 
selective molecular requirements for stable ┙-synuclein binding and retrieval may vary 
between different organelles, such as vesicles or mitochondria, each regulated by organelle-
specific factors present on the membrane or in the cytosol. One potential means to 
characterize ┙-synuclein compartmentalization on discrete organelles is by further refining 
the cell-free binding and dissociation assays, as described above using hypotonically 
permeabilized mouse brain synaptosomes, to specific organelles that are first isolated by 
differential density and centrifugation protocols. Alternatively, detection of organelle-
specific interactors could be done by using inhibitory antibodies to screen for candidates 
known to exist only on defined organelles, as we have done to identify rab3a as an ┙-
synuclein binding partner on synaptic vesicles. Finally, these cell-free assays also offer an 
approach to validate the functional effects of ┙-synuclein interactions identified by various 
genetic or biochemical methodologies by characterizing their consequences on ┙-synuclein 
membrane distribution.  
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